ChartMill assigns a fundamental rating of 2 / 10 to IMUC.
ChartMill assigns a valuation rating of 3 / 10 to IMMUNOCELLULAR THERAPEUTICS (IMUC). This can be considered as Overvalued.
IMMUNOCELLULAR THERAPEUTICS (IMUC) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of IMMUNOCELLULAR THERAPEUTICS (IMUC) is expected to decline by -100% in the next year.
The dividend rating of IMMUNOCELLULAR THERAPEUTICS (IMUC) is 0 / 10 and the dividend payout ratio is 0%.